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Letter to the Editor
Variable phenotype and discrete
alterations of immune phenotypes
inCTPsynthase1deficiency: Report
of 2 siblings
To the Editor:
Loss-of-function homozygous mutations in the CTP synthase 1
(CTPS1) gene in humans have only recently been discovered and
reveal the role of this gene in lymphocyte proliferation.1 To date a
single report including 8 individuals describes a severe clinical
phenotype including early onset of severe chronic viral infections,
recurrent encapsulated bacterial infections, and EBV-related
B-cell non-Hodgkin lymphoma.1
We report 2 further sibling cases of CTSP1 deficiency
identified through whole-exome sequencing (WES), further
illustrating the phenotype of CTPS1 deficiency and demon-
strating the value of WES for rapid diagnosis of primary
immunodeficiency even for conditions whose phenotype is not
well recognized.
The 2 siblings (boy, now 6 years old; girl, now 3 years old)
described in this report are the only children of nonconsangui-
neous and healthy white parents with no personal or family
history of immunodeficiency, autoimmunity, or EBV-related
disorders. Both children had no dysmorphic features and normal
growth.
The boy was born at term and was noted to have a significant
burden of infections from early infancy. He was admitted to
hospital at age 2 months with fever, lethargy, and poor feeding of
unknown cause, responding rapidly to 48 hours of intravenous
antibiotics. At age 7 months, he had an episode of invasive
serotype 19A pneumococcal disease despite prior vaccination
with the 13-valent pneumococcal conjugate vaccine (Prev(e)nar
13, Pfizer Inc, New York, NY) at age 2 and 4 months. At age
16months,while on holiday inTurkey, hewas admitted to hospital
with severe tonsillitis and dehydration.At the age of 34months, he
developed an acute EBV infection with persistent viremia (see
Fig E1 in this article’s Online Repository at www.jacionline.org)
but no features of hemophagocytic lymphohistiocytosis.
In addition to these hospital admissions, he suffered from
recurrent otitis media and lower respiratory tract infections, and
had moderate to severe eczema from the neonatal period. He
developed chronic diarrhea of unknown etiology lasting for
approximately 8 weeks when he was 3.5 years old. An upper
and lower gastrointestinal endoscopic biopsy showed reactive
lymphoid aggregates in the duodenum and colon without signs of
active inflammation, ulceration, or infectious organisms.
The immunologic workup was largely normal (see Table E1
and the Methods section in this article’s Online Repository at
www.jacionline.org). However, he had only moderate responses
to a 13-valent pneumococcal conjugate vaccine booster with
poor persistence2 of vaccine antibodies (Fig 1). He also showed
rapid waning of antibodies against H influenzae type b polysac-
charide and tetanus toxoid protein.
His younger sister first presented at the age of 8 months with a
likely viral illness involving fever, possible meningitis (mild
pleocytosis) and unresponsive episodes along with vomiting, and
prolonged diarrhea. She also suffered from eczema and recurrent
upper and lower respiratory tract infections from age 12 months.
However, she did not have frequent ear infections, had never
suffered from invasive bacterial diseases, and remains EBV
negative by both PCR and serology. Initial immunological testing
was normal (Table E1) apart from a poor response to a booster
dose of pneumococcal conjugate vaccine and undetectable anti-
H influenzae type b IgG concentration despite booster
vaccination.
Detailed analysis of cytokine production in both children
showed a normal TH1 axis and normal TLR responses. However,
IFN-g production in response to T-cell agonists was significantly
reduced, pointing to T-cell impairment (see Fig E2 in this article’s
Online Repository at www.jacionline.org).
Following negative results upon initial investigation for causes
of immunodeficiency, targeted WES was performed on the
affected boy when he was 4 years old. A homozygous variant
within the final nucleotide in intron 17 of the CTPS1 gene
(NM_001905.2:c.1692-1G>C) was thought to be causative (see
the Methods section).
Flow cytometric analysis of lymphocytes at the age of 59 and
25 months, respectively, revealed lymphopenia and marked
deficiency of B cells in the boy (Fig 2, A andB), possibly resulting
from chronic EBV infection (Fig E1). Both children showed a
relative predominance of transitional B cells and a deficiency of
naive B cells (Fig 2, C). The distribution of major T cells
(Fig 2,D) andCD41T-cell subpopulationswas largely unaffected
(Fig 2, E), whereas major disturbances were seen within the
CD81 T-cell compartment (Fig 2, F).
The identification of the CTPS1 mutation has significantly
altered the clinical management of the 2 affected siblings, empha-
sizing the clinical use of next-generation sequencing in children
with unknown immunodeficiencies. The index case has already
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FIG 1. Pneumococcal serotype-specific antibody concentrations before
and after booster vaccination at age 35 months. Pn, Pneumococcal sero-
type. Arrows indicate age at vaccination with the 13-valent pneumococcal
conjugate vaccine (Prev(e)nar 13, Pfizer Inc); the dashed line specifies a
serotype-specific IgG concentration of 0.35 mg/mL.
1
successfully undergone matched unrelated donor hematopoietic
stem cell transplantation (HSCT) using peripheral blood stem
cells following reduced intensity conditioning with fludarabine
and melphalan and in vivo T-cell depletion with alemtuzumab.
He is now 8 months after HSCT at home and doing well without
signs of graft-versus-host disease. The sister is on immunoglob-
ulin replacement therapy and being considered for HSCT.
This report adds to the current literature by highlighting that
CTPS1 deficiency can also manifest with relatively mild clinical
phenotype as seen in the sister of the index case. We suggest that
CTPS1 deficiency should be considered in all patients with a
phenotype of combined immunodeficiency and without alterna-
tive diagnosis.3 An important feature of CTPS1-deficient patients
is that they may present with only subtle laboratory abnormalities
of the humoral immune system despite experiencing severe
bacterial disease. In addition, CTPS1-deficient patients can
have normal immunophenotypes of major T-cell populations
(Fig 2, D) and normal T-cell proliferation to mitogens. We found
increased frequencies of transitional B cells in combination with
reduced frequencies of naive B cells in both children (Fig 2,C). In
the index patient, frequencies of naive, marginal zone, and
memory B cells were greatly reduced (Fig 2, C), likely as a result
of poor EBV control. Reduced numbers of memory B cells were
also found in several patients in the original report1 but here we
show that this finding may not represent an inherent feature of
CTPS1 deficiency and rather a result of chronic EBV infection.
FIG 2. A,Absolute lymphocyte and B-, T-, and NK-cell counts. B, Relative lymphocyte and B-, T-, and NK-cell
values. C, Relative numbers for B-cell subpopulations. D, Relative frequencies of major T-cell subsets. E,
Relative frequencies of CD41 T-cell subpopulations. F, Relative frequencies of CD81 T-cell subpopulations.
DN, Double negative;DP, double positive;NK, natural killer; TCM, central memory T cells; TEM, effector mem-
ory T cells; RTE, recent thymic emigrants.
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Hence, memory B-cell frequencies may be normal in CTPS1-
deficient patients before EBV exposure. Within the T-cell
compartment, we found reduced frequencies of activated CD41
and CD81 T cells in both patients whereas other CD41 T-cell
subpopulations were present at normal frequencies. These
findings are in line with results in 4 of the 8 patients described
in the original report1 who did not show lymphopenia or reduced
numbers of naive CD41 T cells and therefore these recently
suggested diagnostic features4 may not be sensitive in identifying
CTPS1-deficient patients. We found marked alterations of the
CD81 T-cell compartment in our patients, mainly reduced
frequencies of terminally differentiated and memory CD81
subpopulations (Fig 2, F), possibly as a result of both chronic
EBV infection and the underlying defect in CTPS1. Taken
together, CTPS1 deficiency may be suggested in children with
recurrent viral and bacterial infections and reduced frequencies
of activated CD4/81 T cells and abnormal CD81 phenotype
with a predominance of naive CD81 T cells. Abnormalities of
lymphocyte numbers, naive CD41 T-cell, and memory B-cell
frequencies and the capacity of T cells to proliferate upon
exposure to mitogens seem to be variable features and may also
depend on previous exposure to EBV.
CTPS1 deficiency expands the range of primary immune
deficiencies associated with poor EBV control and lymphoprolif-
eration.3 At present very little is known about the clinical pheno-
type or prognosis of patients with CTPS1 deficiency. Our 2
patients presented with clinical features suggestive of combined
immunodeficiency and in contrast to previously described cases,1
the clinical features also included gastrointestinal symptoms
and eczema, possibly as a result of immune dysregulation.
These latter features have not previously been described in
CTPS1-deficient patients.
The utility of next-generation DNA sequencing in the diagnosis
of rare diseases is now widely appreciated.5 This technology
offers rapid and cost-effective detection of known mutations in
PID genes. In this report, we demonstrate that in a clinical setting
where a range of genotypes may be responsible for the observed
phenotype, WES offers a novel approach in establishing a defin-
itive diagnosis affecting the proband and other family members.
We thank the High-Throughput Genomics Group at the Wellcome Trust
Centre for Human Genetics (funded by Wellcome Trust grant reference no.
090532/Z/09/Z and Medical Research Council Hub grant no. G0900747
91070) for the generation of the sequencing data.
Johannes Tr€uck, MD, DPhila
Dominic F. Kelly, MRCP, PhDa
John M. Taylor, PhDb
Anne Kathrin Kienzler, PhDc
Tracy Lester, FRCPath, PhDb
Anneke Seller, FRCPath, PhDb
Andrew J. Pollard, FRCPCH, PhDa
Smita Y. Patel, FRCP, FRCPath, PhDc
From athe Department of Paediatrics, University of Oxford, and the NIHR Oxford
Biomedical Research Centre, Oxford, United Kingdom; bOxford Medical Genetics
Laboratories, Oxford University Hospitals NHS Trust, The Churchill Hospital, Head-
ington, Oxford, United Kingdom; and cthe Clinical Immunology Group, Oxford
NIHR Biomedical Research Centre, United Kingdom. E-mail: johannes.trueck@
kispi.uzh.ch.
This work was supported by the National Institute for Health Research (NIHR) Biomed-
ical Research Centre Oxford with funding from the Department of Health’s NIHR
Biomedical Research Centres funding scheme.
Disclosure of potential conflict of interest: D. F. Kelly has received grants from the
Biotechnology and Biological Sciences Research Council and GlaxoSmithKline
and has received travel support from GlaxoSmithKline and Sanofi-Pasteur. S. Y. Patel
has received grants from the Wellcome Trust and has received payment for lectures
from Biotest and Activis. The rest of the authors declare that they have no relevant
conflicts of interest.
REFERENCES
1. Martin E, Palmic N, Sanquer S, Lenoir C, Hauck F, Mongellaz C, et al. CTP syn-
thase 1 deficiency in humans reveals its central role in lymphocyte proliferation.
Nature 2014;510:288-92.
2. Tr€uck J, Snape MD, Tatangeli F, Voysey M, Yu LM, Faust SN, et al. Pneumococcal
serotype-specific antibodies persist through early childhood after infant immuniza-
tion: Follow-up from a randomized controlled trial. PLoS One 2014;9:e91413.
3. Taylor GS, Long HM, Brooks JM, Rickinson AB, Hislop AD. The immunology of
Epstein-Barr virus-induced disease. Annu Rev Immunol 2015;33:787-821.
4. Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al. Practice
parameter for the diagnosis and management of primary immunodeficiency.
J Allergy Clin Immunol 2015;136:1186-205, e1-78.
5. Casanova J-L, Conley ME, Seligman SJ, Abel L, Notarangelo LD. Guidelines for
genetic studies in single patients: lessons from primary immunodeficiencies. J Exp
Med 2014;211:2137-49.
http://dx.doi.org/10.1016/j.jaci.2016.04.059
J ALLERGY CLIN IMMUNOL
VOLUME nnn, NUMBER nn
LETTER TO THE EDITOR 3
METHODS
Additional immune workup in the index case
In addition to the analysis presented in Table E1, normal results were found
for T-cell receptor V-beta repertoire, T-cell-receptor gene rearrangement exci-
sional circles, CD62 ligand shedding, SLAM-associated protein and X-linked
inhibitor of apoptosis protein protein expression, and IL-2–inducible T-cell ki-
nase expression and genetic analysis.
Whole-exome sequencing
This was done as part of a research project approved by the Southampton
A Research Ethics Committee (reference 12/SC/044), and written informed
consent was obtained from both parents.
Exome capture was performed using the NimbleGen SeqCap EZ Human
Exome Library v2.0, according to the manufacturer’s instructions, and
sequenced using a 2 3 100 bp read protocol on an Illumina HiSeq.
Approximately 15 Gb of sequence was obtained, providing at least
10 3 vertical read depth over approximately 90% of the coding exome, as
specified by the consensus coding sequence project. Reads were aligned to
hg19 with Stampy (v1.0.20)E1 and variant calling of single nucleotide variants
and short insertion and deletionswas undertaken using Platypus (v0.5.2; www.
well.ox.ac.uk/platypus).E2
Variant annotation and analysis was restricted to a targeted panel of 237
immune-related genes (Table E2), using the Illumina VariantStudio data anal-
ysis software (Illumina, Inc, San Diego, Calif). Variants were initially filtered
on a population frequency below 5% within the National Heart, Lung, and
Blood Institute GO Exome Sequencing Project,E3 which reduced the list
from 284 variants to 44 variant calls. All variants were individually assessed
to determine their likely pathogenicity on the basis of ACGS-recommended
best practice guidelines.E4
Subsequent Sanger sequencing demonstrated that this homozygous
nucleotide substitution was present in both affected children and heterozygous
in both unaffected parents. This change has recently been described in several
affectedmembers of families originating from the northwest of EnglandE5 and
disrupts 1 of the 2 invariant nucleotides of the acceptor site and is predicted to
lead to aberrant splicing of intron 17 (Alamut, version 2.4.5; Interactive Bio-
software, Rouen, France) (Fig E3). It is therefore considered to be pathogenic.
Immune phenotyping by flow cytometry
Absolute lymphocyte counts were determined using the BD Multitest,
CD3/CD16:56/CD45/CD19 reagent, and TruCount tubes (both BD
Biosciences, San Jose, Calif) according to the manufacturer’s instructions.
Flow cytometry datawere analyzed with Infinicyt software (Cytognos, Spain).
Boxplots indicate the 5 to 95th percentile and median adopted from Pia˛tosa
et alE6 (for lymphocytes, B cells, and B-cell subpopulations), the 10 to 90th
percentile and median adopted from Shearer et alE7 (for T and natural killer
[NK] cells, memory and activated CD4/81 T-cell subpopulations), and the
mean and 90% tolerance interval adopted from Schatorje et alE8 (for major
T-cell populations and most CD4/81 T-cell subpopulations). Note that gating
strategies for cell populations may differ between cited reports and our report.
Additional notes with regard to the analysis of panels shown in Fig 2:
A, Absolute numbers of lymphocytes (CD451 and scatter characteristics) and
B (CD451CD191), T (CD451CD31), and NK (CD451CD161CD561) cells.
B, Relative lymphocyte and B, T, and NK-cell values as indicated by the
percentage of total CD451 leukocytes (lymphocytes) or CD451 lymphocytes
(B, T, and NK cells). C, Relative numbers for B-cell subpopulations expressed
as a percentage of total CD191 B cells: transitional B cells
(CD272IgD1IgM1CD241CD381); naive B cells (CD272IgD1IgM1); innate
effector/marginal zone B cells (CD271IgD1IgM1); switched memory B cells
(CD271IgD2IgM2); CD27-negative memory B cells (CD272IgD2IgM2);
plasmablasts (CD271CD381CD242); CD21low CD38low activated
B cells (CD21loCD38lo). D, Relative frequencies of major T-cell subsets:
TCR-g/d positive cells (CD451TCRg/d1), TCR-g/d negative cells
(CD451TCRg/d2), CD41T cells (TCRg/d-CD41), CD81 T cells
(TCRg/d2CD81), CD41CD81 double-positive T cells (TCRg/d-CD41CD81),
and CD42CD82 double-negative T cells (TCRg/d2CD42CD82). Relative cell
counts for TCRgd-positive and TCRgd-negative T cells indicate the percentage
of total CD451 lymphocytes. Relative cell counts for CD41, CD81,
double-positive, and double-negative T cells depict the percentage of
CD31TCRgd2 T cells.E,Relative frequencies of CD41 T-cell subpopulations:
Naive T cells (CD45RA1CD271), terminally differentiated T cells (term. diff.;
CD45RA1CD272), central memory T cells (TCM; CD45RA
2CD271), effector
memory T cells (TEM; CD45RA
2CD272), recent thymic emigrants
(CD45RO2CD311CD62L1HLA2DR2), memory T cells (CD45RO1), and
activated T cells (HLA2DR1). Relative cell counts for CD41 naive, term.
diff., TCM, and TEM T cells depict the percentage of total CD4
1 lymphocytes.
Relative cell counts for CD41 memory and activated T cells depict the
percentage of CD31 T cells. F, Relative frequencies of CD81 T-cell
subpopulations: Naive T cells (CD45RO2CD271CCR71), term. diff
T cells (CD45RO2CD272CCR72), TCM (CD45RO
1CD271CCR71), TEM
(CD45RO1CD272CCR72), memory T cells (CD45RO1), and activated
T cells (HLA-DR1). Relative cell counts for naive, term. diff, TCM, and TEM
T cells depict the percentage of total CD81 lymphocytes. Relative cell counts
for memory and activated T cells depict the percentage of CD31 T cells.
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FIG E1. Kinetics of EBV viral load (VL [copies/mL]) and CRP (mg/L) of patient Pat_1.1 during and after the
acute EBV infection at around age 34 months.
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FIG E2. Cytokine studies on both patients (boy, Pat_1.1, and girl, Pat_1.2) and a control. Stimulating agents
are shown above each bar graph, and bars show IFN-g responses to stimulation as bars for both patients in
comparison with a healthy control. IONO, Ionomycin; PMA, phorbol 12-myristate 13-acetate.
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FIG E3. CTPS1 sequence electropherograms for the 4members of the kindred with the c.1692-1G >C variant
(outlined by the black box).
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TABLE E1. Results of immunologic investigations performed in
the 2 siblings
Patient P1.1 (male) P1.2 (female)
Age at evaluation (mo) 42 9
Cell subsets (cells/mm3)
ANC (1.5-8.0) 5.15 2.4
Lymphocytes 2.23 (1.8-5.4) 3.11 (2.6-10.4)
CD31 (normal) 1.81 (1.2-3.4) 1.99 (1.6-6.7)
CD41 (normal) 1.1 (0.8-2.1) 1.45 (1.0-4.6)
CD81 (normal) 0.62 (0.35-1.7) 0.5 (0.4-2.1)
CD191 (normal) 0.25 (0.1-0.5) 0.89 (0.6-2.7)
CD561 (normal) 0.15 (0.1-1.0) 0.2 (0.2-1.2)
T-cell proliferation by
CFSE (using PHA)
Normal ND
Serum immunoglobulins
IgA (normal) (g/L) 1.01 (0.4-2.0) 0.72 (0.2-0.7)
IgG (normal) (g/L) 5.34 (4.9-13.0) 5.58 (3.0-10.9)
IgM (normal) (g/L) 0.62 (0.4-2.5) 0.44 (0.4-2.0)
IgE (normal) (kU/L) 6.49 (5-63) ND
Values in boldface correspond to values outside normal age-matched ranges that are
indicated in parentheses.
ANC, Absolute neutrophil count; CFSE, carboxyfluorescein succinimidyl ester;
ND, not done.
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TABLE E2. List of targeted panel of 237 immune-related genes
ACP5 CD8A IL10 NHP2 SPINK5
ACTB CEBPE IL10RA NKX2-5 STAT1
ADA CFB IL10RB NLRP12 STAT2
ADAM17 CFD IL12 B NLRP3 STAT3
ADAR CFH IL12RB1 NOD2 STAT5B
AICDA CFHR1 IL17F NOP10 STIM1
AIRE CFHR2 IL17RA NRAS STK4
AK2 CFHR3 IL1RN ORAI1 STX11
AP3B1 CFHR4 IL21R PIGA STXBP2
APOL1 CFHR5 IL2RA PIK3CD TAP1
ATM CFI IL2RG PIK3R1 TAP2
BLM CFP IL36RN PLCG2 TAPBP
BLNK CHD7 IL7R PMS2 TAZ
BLOC1S6 CIITA IRAK4 PNP TBK1
BTK COLEC11 IRF8 POLE TBX1
C1QA CORO1A ISG15 PRF1 TCF3
C1QB CR2 ITCH PRKCD TCN2
C1QC CSF2RA ITGB2 PRKDC TERT
C1R CTPS1 ITK PSMB8 THBD
C1S CTSC JAK3 PSTPIP1 TICAM1
C2 CXCR4 KMT2D PTPRC TINF2
C3 CYBA KRAS RAB27A TLR3
C4A CYBB LAMTOR2 RAC2 TMC6
C4B DCLRE1C LCK RAG1 TMC8
C5 DKC1 LIG4 RAG2 TNFRSF13B
C6 DNMT3B LPIN2 RBCK1 TNFRSF13C
C7 DOCK8 LRBA RFX5 TNFRSF1A
C8A ELANE LYST RFXANK TNFRSF4
C8B FADD MAGT1 RFXAP TNFSF12
C9 FAS MALT1 RHOH TRAF3
CARD11 FASLG MASP1 RNASEH2A TRAF3IP2
CARD14 FCN3 MASP2 RNASEH2B TREX1
CARD9 FERMT3 MBL2 RNASEH2C TTC7A
CASP10 FOXN1 MCM4 RNF168 TYK2
CASP8 FOXP3 MEFV RPSA UNC119
CD19 FPR1 MRE11A RTEL1 UNC13D
CD247 G6PC3 MS4A1 SAMHD1 UNC93B1
CD27 G6PD MSH5 SBDS UNG
CD3D GATA2 MTHFD1 SEMA3E USB1
CD3E GFI1 MVK SERPING1 VPS13B
CD3G HAX1 MYD88 SH2D1A VPS45
CD40 ICOS NBN SH3BP2 WAS
CD40LG IFNGR1 NCF1 SLC29A3 WIPF1
CD46 IFNGR2 NCF2 SLC35C1 XIAP
CD59 IGLL1 NCF4 SLC37A4 ZAP70
CD79A IKBKB NFKB2 SLC46A1 ZBTB24
CD79B IKBKG NFKBIA SMARCAL1
CD81 IKZF1 NHEJ1 SP110
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